Walsh G: Biopharmaceutical benchmarks 2006. Nat Biotechnology
2006, 24: 769–776.CrossRef 2. Giezen T, Mantel-Teeuwisse A, Straus S, Schellekens H, Leufkens H, Egberts A: Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008, 300: 1887–1896.CrossRefPubMed 3. Inclone Syetems Incorporated NYN, Bristol-Myers Squibb Co PN: Erbitux (Cetuximab) Package Insert. 2008. 4. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene M: ErbB receptors: from oncogenes to targeted cancer therapies. Journal Clinical Investigation 2007, 117: 2051–2058.CrossRef 5. Rosell R, Robinet G, Szczesna A, Ramlau R, Costenla M, Mennecier B, Pfiefer W, O’Bryne K, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson M, Ellis P, Pilz K, Reck M: Randomized pahse II study of cetuximab plus cisplatin/this website vinorelbine GSK872 in vivo compasred selleckchem with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncology 2008, 19: 362–369.CrossRef
6. Monti M, Motta S: Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers 2007, 22: S53-S61.PubMed 7. Saif MW, Kim R: Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007, 6: 175–182.CrossRefPubMed 8. Leard L, Cho B, Jones K, Hays S, Tope W, Golden J, Hoopes C: Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007, 26: 1340–1344.CrossRefPubMed 9. Patel D, Goldberg R: Cetuximab-associated infusion reactions: pathology and Management. D-malate dehydrogenase Oncology 2006, 20: 1373–1382.PubMed 10. Arnold D, Hohler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Woll E, Herrmann T, Zubel A, Schmoll H: Cetuximab in combination with weekly 5-fluorouracil/folinic
acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncology 2008, 19: 1442–1449.CrossRef 11. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112: 2733–2739.CrossRefPubMed 12. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23: 5568–5577.CrossRefPubMed 13.